M. Kulyk & Associates LLC Buys New Shares in Novo Nordisk A/S (NYSE:NVO)

M. Kulyk & Associates LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 5,860 shares of the company's stock, valued at approximately $606,000.

Several other large investors have also recently bought and sold shares of NVO. Polen Capital Management LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at $718,995,000. FMR LLC raised its stake in Novo Nordisk A/S by 122.7% during the 3rd quarter. FMR LLC now owns 12,077,501 shares of the company's stock valued at $1,098,328,000 after purchasing an additional 6,654,614 shares during the last quarter. Morgan Stanley raised its stake in Novo Nordisk A/S by 96.5% during the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company's stock valued at $838,021,000 after purchasing an additional 4,526,199 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 91.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company's stock valued at $827,354,000 after purchasing an additional 4,350,862 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in Novo Nordisk A/S by 156.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 4,552,481 shares of the company's stock valued at $414,003,000 after buying an additional 2,779,866 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO traded down $1.15 during trading hours on Friday, hitting $131.89. The stock had a trading volume of 2,589,174 shares, compared to its average volume of 4,727,685. The company's fifty day moving average is $128.09 and its two-hundred day moving average is $114.96. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The stock has a market capitalization of $591.86 billion, a price-to-earnings ratio of 45.32, a P/E/G ratio of 1.91 and a beta of 0.43.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an "outperform" rating and a $163.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.